Neil Bhalodkar : No.
Raymond Cohen: No. Okay. All right. So, so, thanks Anthony. I appreciate those questions about this. I think did you have a second. There was a second.
Neil Bhalodkar : Thoughts on M&A
Raymond Cohen: Oh, thoughts on M&A. Thank you. Thank you. So, look, we’re – as you might imagine, the words out that Axonics is inquisitive, okay, so we have a lot of folks pitching up at all kinds of very interesting things, but we’re going to be very disciplined. And if we’re going to acquire something, it have to fit perfectly in our strategy. We’ve gotten this question many, many times in different forms. We’re focused on the incontinence business. And that’s where we’re focused. That’s such an underserved population that we don’t want to go off into adjacent markets and pick up other products. We’re obviously biased towards women just as a general sense, not to say that we’re, if men have incontinence, we want to treat them, as well.
But you’re going to see an approach where we’ll tuck some stuff in if it makes sense. And if there’s a bigger idea out we are not going to be afraid to pull the trigger, but we’re being very disciplined about this. We’re constantly looking at what’s out there. And people are approaching us in the same way. So I don’t think we’re going to surprise anybody with something, like buying a stereo company or something like that.
Anthony Petrone : Very helpful. Thank you.
Raymond Cohen: Thanks Anthony.
Operator: Thank you. Our next question comes from the line of Michael Sarcone from Jefferies. Your question please.
Michael Sarcone : Hey, good afternoon, Ray, Dan and Neil. First question, I just have one or two on the lead placement. technology acquisition. Are there any next milestones before getting to FDA approval? Have you already submitted its development already complete?
Raymond Cohen: So, we haven’t submitted, of course not. We just acquired the technology a week ago. We have to do the validation verification testing and have the product “manufacturable”. Those are the things that we’re now starting to work on and we’re going to look to get a filing to the FDA as fast as possible. So we’re anxious to get this done and we will do it, with our standard velocity and care, right. But we don’t want to give a specific timeline. I mean, we said, certainly by sometime next year. Obviously, we’re going to work hard to go as fast as we can and get it done as quickly as we can, because there’s a lot of interest in that product.
Michael Sarcone : Understood and one just one last one. Do you have any color on the economics of the device and the potential margin impact for Axonics?
Dan Dearen: Well, look, let’s just say this. The margin won’t go down because of this acquisition.
Michael Sarcone : Okay. That’s correct
Dan Dearen: Well it’s slippy, but think, that’s the right answer.
Operator: Thank you. This does conclude the question and answer session of today’s program. I’d like to hand the program back to Raymond Cohen for any further remarks.
